Biotech - Technical Analysis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: EepOpp who wrote (420)	6/12/2002 10:13:06 PM
From: Jibacoa	Read Replies (1) of 544

See comments by Adam Feuerstein at T.S.C. (No specific date period given for when they forsee FluMist being approved.) thestreet.com "Medimmune (MEDI:Nasdaq - news - commentary - research - analysis) also contributed to Tuesday's gloom after executives -- speaking at the Goldman Sachs confab -- continue to preach caution about the chances for quick approval of its FluMist vaccine. Growth-hungry biotech investors want Medimmune to get FluMist on the market in time for this winter's flu season. But company executives are managing expectations because there's still a good chance that FluMist isn't ready in time. Medimmune fell $3.19, or 10.5%, to $27.15 Tuesday". Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next